Biokin's EGFRxHER3 ADC succeeds in Chinese lung cancer trial, boosting BMS global hopes
Chinese biotech Biokin reported that its bispecific antibody-drug conjugate targeting EGFR and HER3 met its primary endpoint in a late-stage trial for a genetically defined lung cancer subtype in China. The positive result raises confidence in a parallel global study being run by partner Bristol Myers Squibb. This marks the fourth successful cancer trial for the candidate in China.
The late-stage result adds to a growing body of evidence for this dual-targeting therapy, which is designed to engage two distinct receptors on tumor cells. For Biokin, the outcome strengthens its domestic pipeline and validates its research platform, while for Bristol Myers Squibb, it offers reassurance as the partner advances a broader international registration effort. Lung cancer remains one of the most common malignancies worldwide, and targeted approaches for specific genetic subtypes have become a major focus of drug development. The candidate's repeated success across multiple Chinese trials suggests consistent efficacy signals, though the global study's outcome will ultimately determine its wider availability.
If the global trial mirrors these results, patients with this specific lung cancer subtype could gain a new treatment option that may extend survival or improve quality of life. Oncologists might gain a more precise tool for matching therapy to tumor genetics, potentially shifting standard practice. However, regulatory approvals, manufacturing capacity, and pricing will shape real-world access, particularly in lower-resource settings. The collaboration also highlights how cross-border partnerships are accelerating oncology innovation, which could benefit patients worldwide while raising questions about equitable distribution of novel therapies.